Artiva Biotherapeutics, Inc. reported $251K of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $251K (to Q4 2024). Net income: −$91M, trailing twelve months to Q2 2026. Free cash flow: −$77M, trailing twelve months to Q2 2026. EPS: −$3.30, trailing twelve months to Q2 2026.

ARTVArtiva Biotherapeutics, Inc.

Healthcare

$6.81+135% 1Y

$6.81

$2.7452 weeks$13.39

ARTV as reported

Artiva Biotherapeutics, Inc. reported $251K of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$251K

Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied

Net income: −$91M
Net income · +21% year on year · trailing twelve months to Q2 2026
Free cash flow: −$77M
Free cash flow · +8.6% year on year · trailing twelve months to Q2 2026
EPS: −$3.30
EPS · +160% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ARTV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$251K	n/a	Q4 2024 · 6 quarters behind
Net income	−$91M	+21%	Q2 2026
EPS	−$3.30	+160%	Q2 2026
Operating margin	−1645%	n/a	Q1 2024 · 9 quarters behind
Net margin	−1588%	n/a	Q1 2024 · 9 quarters behind
ROE	−66%	n/a	Q2 2026
ROA	−56%	n/a	Q2 2026
Free cash flow	−$77M	+8.6%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.